VYALEV SOLUTION

País: Canadà

Idioma: anglès

Font: Health Canada

ingredients actius:

FOSLEVODOPA; FOSCARBIDOPA

Disponible des:

ABBVIE CORPORATION

Codi ATC:

N04BA07

Designació comuna internacional (DCI):

FOSLEVODOPA AND DECARBOXYLASE INHIBITOR

Dosis:

240MG; 12MG

formulario farmacéutico:

SOLUTION

Composición:

FOSLEVODOPA 240MG; FOSCARBIDOPA 12MG

Vía de administración:

SUBCUTANEOUS

Unidades en paquete:

15G/50G

tipo de receta:

Prescription

Resumen del producto:

Active ingredient group (AIG) number: 0264641001; AHFS:

Estat d'Autorització:

APPROVED

Data d'autorització:

2023-05-03

Fitxa tècnica

_VYALEV (foslevodopa/foscarbidopa) _
_ _
_ _
_Page 1 of 53_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
VYALEV™
foslevodopa/foscarbidopa solution
Solution, 240 mg/mL foslevodopa and 12 mg/mL foscarbidopa,
subcutaneous infusion
Antiparkinson Agent
ATC Code: N04BA07
AbbVie Corporation
8401 Trans-Canada Highway
St-Laurent, Qc H4S 1Z1
Date of Initial Authorization:
MAY 03, 2023
Submission Control Number: 263826
_ _
_VYALEV (foslevodopa/foscarbidopa solution) _
_ _
_ _
_Page 2 of 53_
RECENT MAJOR LABEL CHANGES
SECTION
DATE
None
N/A
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
............................................................................................
2
TABLE OF CONTENTS
..............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................................
4
1
INDICATIONS
...............................................................................................................
4
1.1
Pediatrics
................................................................................................................
4
1.2
Geriatrics
................................................................................................................
4
2
CONTRAINDICATIONS
.................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
............................................................ 5
4
DOSAGE AND ADMINISTRATION
.................................................................................
6
4.1
Dosing Considerations
............................................................................................
6
4.2
Recommended Dose and Dosage Adjustment
....................................................... 6
4.4
Administration
.......................................................